Novo Nordisk and Eli Lilly Clash Over the GLP-1 Prize After Q2 Results
Eli Lilly reported $22.97 billion in Q2 revenue while Novo Nordisk posted a 21.9% EPS beat and its oral Wegovy pill surpassed 5 million U.S. prescriptions. The two companies are intensifying competition for the obesity market, with differences emerging in drug formats, market share, valuations, and near-term risks.